lazertinib,amivantamab
yuhan corp,oscotec,janssen,genmab
['lcsm,(-blcsm)', 'lazertinib', 'chrysalis,(-chrysalis2),(-chrysalis-2),(-chrysalis 2)']
#lcsm #asco22 dr. catherine shu presenting chrysalis -2 , phase 2 study of amivantamab and lazertinib heavily pre treated egfr mutant population 
Assistant Professor, Thoracic Oncologist, University of Minnesota | Masonic Cancer Center